Article

Dr. Gary Novack: State of glaucoma pharmaceuticals, what future holds

Gary D. Novack, PhD, president of PharmaLogic Development, co-moderated an industry panel discussion on glaucoma pharmaceuticals Friday during Glaucoma 360. Watch Dr. Novack outline the state of glaucoma drug therapy and where the future is headed.

Gary D. Novack, PhD, president of PharmaLogic Development, co-moderated an industry panel discussion on glaucoma pharmaceuticals Friday during the 4th Annual Glaucoma 360 New Horizons Forum. Watch as Dr. Novack outlines the state of glaucoma drug therapy and where the future is headed.

Related Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Dr. Amir Ghanipour discusses light adjustable lenses for cataracts at EyeCon 2024
Related Content
Site Logo
October 8th 2024

Eyes on the Prize: Winning Strategies to Help Your Practice Thrive

Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

New study identifies common mechanism behind age-related macular degeneration and related macular dystrophies
October 8th 2024

New study identifies common mechanism behind age-related macular degeneration and related macular dystrophies

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
August 30th 2024

Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy

ASU researchers tap AI to help people see more clearly
October 7th 2024

ASU researchers tap AI to help people see more clearly

Brain-to-eye β-amyloid transport and Alzheimer's Disease retinopathy
October 7th 2024

Brain-to-eye β-amyloid transport and Alzheimer's Disease retinopathy

© 2024 MJH Life Sciences

All rights reserved.